Laszlo G. Puskas

Laszlo G. Puskas

Auto-generated profile, based on publicly available information

Laszlo G. Puskas

Laboratory of Functional Genomics, Core Facility, HUN-REN Biological Research Centre, Szeged, Hungary

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Open access
VSViktoria Szuts
Viktoria Szuts
DMDalma Ménesi
Dalma Ménesi
ZVZoltán Varga-Orvos
Zoltán Varga-Orvos
ÁZÁgnes Zvara
Ágnes Zvara
NHNazanin Houshmand
Nazanin Houshmand
NJNorbert Jost
Norbert Jost
Dilated cardiomyopathy (DCM) is a multifactorial disease characterized by left ventricular dilation that is associated with systolic dysfunction and increased action potential duration. The Kir2.x K+channels (encoded by KCNJ genes) regulate the inward rectifier current (IK1) contributing to the final repolarization in cardiac muscle. Here, we describe the transitions in the gene expression profiles of 4 KCNJ genes from healthy or dilated cardiomyopathic human hearts. In the healthy adult ventricles, KCNJ2, KCNJ12, and KCNJ4 (Kir2.1–2.3, respectively) genes were expressed at high levels, while expression of the KCNJ14 (Kir2.4) gene was low. In DCM ventricles, the levels of Kir2.1 and Kir2.3 were upregulated, but those of Kir2.2 channels were downregulated. Additionally, the expression of the DLG1 gene coding for the synapse-associated protein 97 (SAP97) anchoring molecule exhibited a 2-fold decline with increasing age in normal hearts, and it was robustly downregulated in young DCM patients. These adaptations could offer a new aspect for the explanation of the generally observed physiological and molecular alterations found in DCM.

31 March 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
Gábor J. SzebeniGábor J. Szebeni
Gábor J. Szebeni
NGNikolett Gémes
Nikolett Gémes
DHDániel Honfi
Dániel Honfi
ESEnikő Szabó
Enikő Szabó
PNPatrícia Neuperger
Patrícia Neuperger
ABAttila Balog
Attila Balog
Background: Vaccine-induced immunity is essential for controlling the COVID-19 pandemic. Data on humoral and cellular immunogenicity and safety of different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases (RMDs) are limited.Methods: A single center observational study evaluated the immunogenicity and safety of the two-dose regimen of the BBIBP-CorV inactivated, Gam-COVID-Vac and AZD1222 adenovirus-based, and BNT162b2 and mRNA-1273 mRNA-based vaccines in patients with RMDs (n = 89) compared with healthy controls (n = 74). Neutralizing anti-RBD (receptor binding domain) specific antibodies and SARS-CoV-2 specific T-cell response were measured one and four months after the second vaccine dose in parallel with vaccination efficacy and safety.Results: Disease-specific comparison showed that antibody response at four months was higher in spondylarthropathies compared to rheumatoid arthritis and autoimmune RMDs. Risk factors for reduced immunogenicity included longer disease duration, positive immunoserological profile and anti-CD20 therapy of patients. The rate of positive anti-RBD antibody response for healthy controls versus patients after 4 months post vaccination was 69% vs. 55% for the inactivated viral vaccine BBIBP-CorV, 97% vs. 53% for the pooled data of adenovirus vector-based vaccines Gam-COVID-Vac and AZD1222, or 100% vs. 81% for the pooled data of mRNA vaccines BNT162b2 and mRNA-1273, respectively. Patients who received the Gam-COVID-Vac or mRNA-1273 vaccines had a higher proportion of TNF-α producing CD4+ T-cells upon SARS-CoV-2 antigen stimulation compared to the inactivated viral vaccine.Conclusion: All five investigated vaccines were immunogenic in the majority of patients and healthy controls with variable antibody and T-cell response and an acceptable safety profile.

22 July 2021 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
ÁTÁdám Tajti
Ádám Tajti
KSKármen Emőke Szabó
Kármen Emőke Szabó
NPNóra Popovics-Tóth
Nóra Popovics-Tóth
JIJavad Iskanderov
Javad Iskanderov
Franc PerdihFranc Perdih
Franc Perdih
Erika BálintErika Bálint
Erika Bálint
A new approach for the synthesis of 2-amino-4H-chromenes containing a phosphonate or phosphine oxide moiety was developed, and several products showed moderate activity against a number of cell lines.

10 March 2021 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
JBJózsef Ágoston Balog
József Ágoston Balog
VHViktor Honti
Viktor Honti
ÉKÉva Kurucz
Éva Kurucz
BKBeáta Kari
Beáta Kari
LPLászló G. Puskás
László G. Puskás
Gábor J. SzebeniGábor J. Szebeni
Gábor J. Szebeni
Single-cell mass cytometry (SCMC) combines features of traditional flow cytometry (i.e., fluorescence-activated cell sorting) with mass spectrometry, making it possible to measure several parameters at the single-cell level for a complex analysis of biological regulatory mechanisms. In this study, we optimized SCMC to analyze hemocytes of the Drosophila innate immune system. We used metal-conjugated antibodies (against cell surface antigens H2, H3, H18, L1, L4, and P1, and intracellular antigens 3A5 and L2) and anti-IgM (against cell surface antigen L6) to detect the levels of antigens, while anti-GFP was used to detect crystal cells in the immune-induced samples. We investigated the antigen expression profile of single cells and hemocyte populations in naive states, in immune-induced states, in tumorous mutants bearing a driver mutation in the Drosophila homologue of Janus kinase (hopTum) and carrying a deficiency of the tumor suppressor gene lethal(3)malignant blood neoplasm-1 [l(3)mbn1], as well as in stem cell maintenance-defective hdcΔ84 mutant larvae. Multidimensional analysis enabled the discrimination of the functionally different major hemocyte subsets for lamellocytes, plasmatocytes, and crystal cells, and delineated the unique immunophenotype of Drosophila mutants. We have identified subpopulations of L2+/P1+ and L2+/L4+/P1+ transitional phenotype cells in the tumorous strains l(3)mbn1 and hopTum, respectively, and a subpopulation of L4+/P1+ cells upon immune induction. Our results demonstrated for the first time that SCMC, combined with multidimensional bioinformatic analysis, represents a versatile and powerful tool to deeply analyze the regulation of cell-mediated immunity of Drosophila.

1 January 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
JBJózsef Ágoston Balog
József Ágoston Balog
KÁKemény Ágnes
Kemény Ágnes
LPLaszlo G. Puskas
Laszlo G. Puskas
SBSzilard Burcsar
Szilard Burcsar
ABAttila Balog
Attila Balog
Gábor J. SzebeniGábor J. Szebeni
Gábor J. Szebeni
There is a current imperative to reveal more precisely the molecular pathways of early onset of systemic autoimmune diseases (SADs). The investigation of newly diagnosed drug‐naive SAD patients might contribute to identify novel disease‐specific and prognostic markers. The multiplex analysis of 30 plasma proteins in 60 newly diagnosed drug‐naive SADs, such as RA (rheumatoid arthritis, n = 31), SLE (systemic lupus erythematosus, n = 19), and SSc (systemic scleroderma, n = 10) patients, versus healthy controls (HCs, n = 40) was addressed. Thirty plasma cytokines were quantified using the Procarta Plex™ panel. The higher expression of IL‐12p40, IL‐10, IL‐13, IFN‐γ, M‐CSF, IL‐4, NTproBNP, IL‐17A, BMP‐9, PYY (3‐36), GITRL, MMP‐12, and TNFRSF6 was associated with RA; IL‐12p40, M‐CSF, IL‐4, GITRL, and NTproBNP were higher in SLE; or NTproBNP, PYY (3‐36), and MMP‐12 were increased in SSc over HCs, respectively. The cleaved peptide tyrosine tyrosine (PYY 3‐36) was elevated in RA (361.6 ± 47.7 pg/ml) vs. HCs (163.96 ± 14.5 pg/ml, mean ± SEM, ∗∗∗p = 4 × 10−5). The CI (95%) was 268.05‐455.16 pg/ml for RA vs. 135.55‐192.37 pg/ml for HCs. The elevated PYY (3‐36) level correlated significantly with the increased IL‐4 or GITRL concentration but not with the clinical scores (DAS28, CRP, ESR, RF, aMCV). We are the first to report cleaved PYY (3‐36) as a specific plasma marker of therapy‐naive RA. Additionally, the multiplex plasma protein analysis supported a disease‐specific cytokine pattern in RA, SLE, and SSc, respectively.

8 January 2026 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
EVErika Viragh
Erika Viragh
LALenke Asztalos
Lenke Asztalos
MFMichaela Fenckova
Michaela Fenckova
TSTamas Szlanka
Tamas Szlanka
ZGZoltan Gyorgypal
Zoltan Gyorgypal
ZAZoltan Asztalos
Zoltan Asztalos
Pre-Pulse Inhibition (PPI) is a neural process where suppression of a startle response is elicited by preceding the startling stimulus (Pulse) with a weak, non-startling one (Pre-Pulse). Defective PPI is widely employed as a behavioural endophenotype in humans and mammalian disorder-relevant models for neuropsychiatric disorders. We have developed a user-friendly, semi-automated, high-throughput-compatible Drosophila light-off jump response PPI paradigm, with which we demonstrate that PPI, with similar parameters measured in mammals, exists in adults of this model organism. We report that Drosophila PPI is affected by reduced expression of Dysbindin and both reduced and increased expression of Nmdar1 (N-methyl-D-aspartate receptor 1), perturbations associated with schizophrenia. Studying the biology of PPI in an organism that offers an abundance of genetic tools and a complex and well characterized connectome will greatly facilitate our efforts to gain deeper insight into the aetiology of human mental disorders, while reducing the need for mammalian models.